Mostrar el registro sencillo del ítem

MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica

dc.contributor.advisorRamirez Santana, Carolina
dc.contributor.advisorCruz Baquero, Claudia
dc.contributor.authorMayorga Jimenez, Juana Camila
dc.date.accessioned2024-08-07T00:15:34Z
dc.date.available2024-08-07T00:15:34Z
dc.date.issued2024
dc.identifier.urihttps://repositorio.unicolmayor.edu.co/handle/unicolmayor/7033
dc.description.abstractEl presente proyecto de investigación tiene como objetivo evaluar la proteína MCP4 como biomarcador candidato para el diagnóstico de la Esclerosis Sistémica, una enfermedad autoinmune que implica vasculopatía, respuesta inmune desregulada y fibrosis. Esta enfermedad se presenta frecuentemente en las mujeres, en una edad promedio de 45 años. A pesar de tener una prevalencia baja, su mortalidad es alta y ha sido clasificada en Colombia como una enfermedad huérfana, debido a su heterogeneidad en su presentación clínica es de difícil tratamiento y diagnóstico. La detección temprana de esta enfermedad es fundamental para un manejo clínico efectivo, es por ello que investigadores están en busca de un biomarcador que permita un diagnóstico temprano, mejorando la calidad de vida del paciente. Se propone la proteína MCP4 como biomarcador de diagnóstico para Esclerosis Sistémica basado en su implicación en la fisiopatología de la enfermedad. Para su estudio, se llevará a cabo la recolección de muestras de suero sanguíneo de pacientes diagnosticados con Esclerosis MCP4 COMO BIOMARCADOR DE ESCLEROSIS SISTEMICA Sistémica y un grupo de individuos sanos como controles. Se analizarán los niveles séricos de la proteína MCP4 y se evaluará su correlación con parámetros clínicos pertinentes. Los resultados de esta investigación pretenden contribuir al diagnóstico temprano de la esclerosis sistémica y a una comprensión de la fisiopatología de este trastorno.spa
dc.description.tableofcontentsINDICE DE FIGURAS INDICE DE TABLAS RESUMEN INTRODUCCIÓN 1. ANTECEDENTES 2. MARCO REFERENCIAL 2.1 Esclerosis sistémica (ES) 2. 2 Epidemiología 2.3 Manifestaciones clínicas 2.3.1 Afectación microvascular 2. 4 Fisiopatología de la esclerosis sistémica 2.5 Factores ambientales, genéticos y epigéneticos 2.6 Vasculopatía 2.7 Respuesta inmune 2.7.1 Inmunidad innata 2.7. 2 Inmunidad adaptativa 2.8 Citoquinas implicadas en la Esclerosis Sistémica 2.9 Fibrosis 2.9.1 Pericitos y células musculares lisas 2.9.2 Fibroblastos 2.10 Criterios de clasificación 2.11 Evaluación de autoanticuerpos 2.12 Tratamiento 2.13 Biomarcadores 2.13.1 Biomarcadores séricos propuestos para Esclerosis Sistémica 2.14 Proteínas quimioatrayentes MCP Y MCP-4/CCL13 2.14.1 Estructura proteica de MCP4 2.14.2 MCP4 en el proceso de inflamación 2.14.3 MCP4 y enfermedades autoinmunes 2.14.4 MCP4 y ES 3. DISEÑO METODOLOGICO 3.1 Universo, población y muestras 3.2 Hipótesis, variables e indicadores 3.2.1 Hipótesis 3.2.2 Variables 3.2.3 Indicadores 3.3 Objetivos 3.4 Técnicas y procedimientos 3.4.1 Obtención de las muestras 3.4.2 Evaluación de la proteína MCP4 en suero 3.4.3 Análisis Estadístico 4. RESULTADOS 4.1 Estado sociodemográfico de pacientes con Esclerosis Sistémica 4.2 Estado clínico de pacientes con Esclerosis Sistémica 4.2.1 Comorbilidades 4.2.2 Poliautoinmunidad 4.2.3 Criterios ACR/EULAR 2013 4.2.4 Tipo de Esclerosis Sistémica según su extensión cutánea 4.3 Identificación de la proteína MCP4 en pacientes con Esclerosis Sistémica 4.3.1 Curva ROC y umbral de detección de la proteína MCP4 4.3.2 Prueba Mann Whitney 4.4 Rol de la proteína MCP4 en la Esclerosis Sistémica 4.4.1 Características sociodemográficas 4.4.2 Comorbilidades asociadas, poliautoinmunidad y tratamiento 5. DISCUSIÓN 6. CONCLUSIONES 7. REFERENCIAS BIBLIOGRAFICASspa
dc.format.extent72p.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Colegio Mayor de Cundinamarcaspa
dc.rightsDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.titleMCP4 como biomarcador de diagnóstico en Esclerosis Sistémicaspa
dc.typeTrabajo de grado - Pregradospa
dc.description.degreelevelPregradospa
dc.description.degreenameBacteriólogo(a) y Laboratorista Clínicospa
dc.publisher.facultyFacultad de Ciencias de la Saludspa
dc.publisher.programBacteriología y Laboratorio Clínicospa
dc.relation.referencesJorge Mario Palmezano-Díaz, Claudia Lucía Figueroa-Pineda, Reynaldo Mauricio Rodríguez-Amaya, Lisette Katherine Plazas-Rey. Prevalence and characterization of autoimmune diseases in patients older than 13 years in a hospital of Colombia. Medicina interna de Mexico. 2018;34(4).spa
dc.relation.referencesAbul K. Abbas AHLSP. Mecanismos de autoinmunidad . In: Inmunología celular y molecular. 9th ed. 2018.spa
dc.relation.referencesNicole JA, Iván GA. Inmunopatogenia de las enfermedades autoinmunes. Revista Médica Clínica Las Condes. 2012 Jul;23(4):464–72.spa
dc.relation.referencesLerner A, Jeremias P, Matthias T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2016 May 5;3(4):151–5.spa
dc.relation.referencesLondoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD- Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Revista Colombiana de Reumatología. 2018 Oct;25(4):245–56.spa
dc.relation.referencesRosendahl A, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar 2;38(3):187–95.spa
dc.relation.referencesJ. J. Alegre Sancho EBCICVNFLJICJARI. Esclerosis sistemica . In: Enfermedades reumáticas: Actualización SVR. Valencia: Hospital Universitario Dr. Peset;spa
dc.relation.referencesJerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol. 2022 Nov;87(5):937– 54.spa
dc.relation.referencesBobeica C, Niculet E, Halip A, Gheuca-Solovastru L, Draganescu M, Popescu I, et al. Predictive value of immunological markers in systemic sclerosis. Exp Ther Med. 2021 Jul 14;22(3):994.spa
dc.relation.referencesFurue M, Mitoma C, Mitoma H, Tsuji G, Chiba T, Nakahara T, et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunol Res. 2017 Aug 9;65(4):790–7.spa
dc.relation.referencesSandra S. Arango V. Biomarkers for the evaluation of human health risks. Revista Facultad Nacional de Salud Pública. 2012;spa
dc.relation.referencesCoffey C, Radwan Y, Sandhu A, Crowson CS, Bauer P, Matteson E, et al. POS0838 EPIDEMIOLOGY AND TRENDS IN SURVIVAL OF SYSTEMIC SCLEROSIS IN OLMSTED COUNTY: A POPULATION-BASED STUDY (1980-2018). Ann Rheum Dis. 2021 Jun 19;80(Suppl 1):673.1-673.spa
dc.relation.referencesMANNO RL, WIGLEY FM, GELBER AC, HUMMERS LK. Late-age Onset Systemic Sclerosis. J Rheumatol. 2011 Jul;38(7):1317–25.spa
dc.relation.referencesBergamasco A, Hartmann N, Wallace L, Verpillat P. <p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>. Clin Epidemiol. 2019 Apr;Volume 11:257–73.spa
dc.relation.referencesThe Lancet. Reducing the cost of rare disease drugs. The Lancet. 2015 Feb;385(9970):746.spa
dc.relation.referencesMinSalud. Resolución 023 de 2023- Enfermedades huerfanas. Ministerio de Salud y Protección Social, 023 Colombia; Jan 4, 2023.spa
dc.relation.referencesMinisterio de salud. Enfermedades huerfanas. 2023 Jan.spa
dc.relation.referencesCastro S V, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med. 2010 Feb;4(1):133–47.spa
dc.relation.referencesArron JR. Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. Curr Opin Rheumatol. 2021 Nov;33(6):480–5.spa
dc.relation.referencesHasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX 3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64(1).spa
dc.relation.referencesO’Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-Hackenberg L, Hynan LS, et al. Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea. Journal of Investigative Dermatology. 2017 Aug;137(8):1663– 70.spa
dc.relation.referencesLi L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.spa
dc.relation.referencesLAMKHIOUED B, GARCIA-ZEPEDA EA, ABI-YOUNES S, NAKAMURA H, JEDRZKIEWICZ S, WAGNER L, et al. Monocyte Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma. Am J Respir Crit Care Med. 2000 Aug 1;162(2):723–32.spa
dc.relation.referencesIwamoto T, Okamoto H, Iikuni N, Takeuchi M, Toyama Y, Tomatsu T, et al. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Apr;45(4):421– 4.spa
dc.relation.referencesTruchetet ME, Brembilla NC, Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021 Sep 6;64(3):262–83.spa
dc.relation.referencesUnidad de enfermedades autoinmunes: experiencia de un centro. Revista Uruguaya de Medicina Interna. 2020 Oct 10;05(03).spa
dc.relation.referencesArnett FC. HLA and Autoimmunity in Scleroderma (Systemic Sclerosis). Int Rev Immunol. 1995 Jan 10;12(2–4):107–28.spa
dc.relation.referencesDiot E. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med. 2002 Aug 1;59(8):545–9.spa
dc.relation.referencesGarabrant DH. Scleroderma and Solvent Exposure among Women. Am J Epidemiol. 2003 Mar 15;157(6):493–500.spa
dc.relation.referencesOlink [Internet]. 2023. Proximity Extension Assay (PEA) technology.spa
dc.relation.referencesYanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).spa
dc.relation.referencesGabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989–2003.spa
dc.relation.referencesMónica Ferrer Gracia, Laura María Cuadra Giménez, María de las Mercedes Díez Angulo, Alaitz Saiz Ferrer, María Sanmartín Xifré, Raúl Fernández Peñarroya. Esclerodermia: aspectos conceptuales, epidemiológicos, etiopatogénicos y clínicos. Artículo monográfico. Revista sanitaria de Investigación. 2021;spa
dc.relation.referencesRubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):208–19.spa
dc.relation.referencesFernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012–2016. J Scleroderma Relat Disord. 2020 Jun 19;5(2):137–42.spa
dc.relation.referencesVarga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017 Sep 19;2(3):137–52.spa
dc.relation.referencesRuiz Gutiérrez L, Pérez Gómez A. Protocolo diagnóstico del fenómeno de Raynaud. Medicine - Programa de Formación Médica Continuada Acreditado. 2013;11(32):1997–2000.spa
dc.relation.referencesChoi E, Henkin S. Raynaud’s phenomenon and related vasospastic disorders. Vascular Medicine. 2021 Feb 10;26(1):56–70.spa
dc.relation.referencesThulesius O. Methods for the evaluation of peripheral vascular function in the upper extremities. Acta Chir Scand Suppl. 1976;465:53–4.spa
dc.relation.referencesOlga Lidia Vera Lastra. Esclerosis sistémica. Medicina Interna de México. 2006 May;22(3).spa
dc.relation.referencesShapiro SC, Wigley FM. Treating Raynaud phenomenon: Beyond staying warm. Cleve Clin J Med. 2017 Oct;84(10):797–804.spa
dc.relation.referencesConsejo general de colegios oficiales de farmaceuticos. ESCLEROSIS SISTÉMICA (ESCLERODERMIA). Punto farmacologico . 2017;spa
dc.relation.referencesKhanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–8.spa
dc.relation.referencesAspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.spa
dc.relation.referencesHerrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022 May 15;18(5):276–85.spa
dc.relation.referencesJiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis cutis y calcifilaxis. Actas Dermosifiliogr. 2015 Dec;106(10):785–94.spa
dc.relation.referencesWilkinson JM, Halland M. Esophageal Motility Disorders. Am Fam Physician. 2020 Sep 1;102(5):291–6.spa
dc.relation.referencesCentros para el control y prevencion de enfermedades. Información sobre la telangiectasia hemorrágica hereditaria. 2013.spa
dc.relation.referencesJanosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989 Dec;19(3):191–200.spa
dc.relation.referencesSteen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014 Oct;43(10):e305–14.spa
dc.relation.referencesLock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997 May;92(5):763–71.spa
dc.relation.referencesAzarbani N, Javadzadeh A, Mohseni I, Jalali A, Andalib E, Poormoghim H. Association of Musculoskeletal and Radiological Features with Clinical and Serological Findings in Systemic Sclerosis: A Single-Centre Registry Study. Mediterr J Rheumatol. 2020;31(3):341.spa
dc.relation.referencesPaloma García de la Peña Lefebvre. Esclerosis sistémica. Sociedad Española de Reumatología Pediátrica . 2020;173–85.spa
dc.relation.referencesSobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis – multidisciplinary disease: clinical features and treatment. Rheumatology. 2019 Sep 24;57(4):221–33.spa
dc.relation.referencesDe Pieri A, Korman BD, Jüngel A, Wuertz‐Kozak K. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. Adv Biol. 2021 Apr 15;5(4).spa
dc.relation.referencesMarie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol. 2015 Sep 4;37(5):463–73.spa
dc.relation.referencesLuo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: Genetics and epigenetics. J Autoimmun. 2013 Mar;41:161–7.spa
dc.relation.referencesOuchene L, Muntyanu A, Lavoué J, Baron M, Litvinov I V., Netchiporouk E. Toward Understanding of Environmental Risk Factors in Systemic Sclerosis. J Cutan Med Surg. 2021 Mar 28;25(2):188–204.spa
dc.relation.referencesDENTON CP, BICKERSTAFF MCM, SHIWEN X, CARULLI MT, HASKARD DO, DUBOIS RM, et al. SERIAL CIRCULATING ADHESION MOLECULE LEVELS REFLECT DISEASE SEVERITY IN SYSTEMIC SCLEROSIS. Rheumatology. 1995;34(11):1048–54.spa
dc.relation.referencesBagabir RA, Syed F, Rautemaa R, McGrouther DA, Paus R, Bayat A. Upregulation of Toll-Like Receptors (TLRs) 6, 7, and 8 in Keloid Scars. Journal of Investigative Dermatology. 2011 Oct;131(10):2128–30.spa
dc.relation.referencesBhattacharyya S, Varga J. Emerging Roles of Innate Immune Signaling and Toll-Like Receptors in Fibrosis and Systemic Sclerosis. Curr Rheumatol Rep. 2015 Jan 22;17(1):2.spa
dc.relation.referencesTan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology. 2006 Jun 1;45(6):694–702.spa
dc.relation.referencesAssassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum. 2010 Feb;62(2):589–98.spa
dc.relation.referencesSaigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proceedings of the National Academy of Sciences. 2015 Dec 8;112(49):15136–41.spa
dc.relation.referencesBossini-Castillo L, Martín JE, Díaz-Gallo LM, Rueda B, Martín J. Genética de la esclerodermia. Reumatol Clin. 2010 Sep;6:12–5.spa
dc.relation.referencesBrkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016 Aug;75(8):1567–73.spa
dc.relation.referencesStifano G, Christmann RB. Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence? Curr Rheumatol Rep. 2016 Jan 23;18(1):2.spa
dc.relation.referencesZhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation. The Journal of Immunology. 2002 Mar 15;168(6):3088–98.spa
dc.relation.referencesLescoat A, Lecureur V, Roussel M, Sunnaram BL, Ballerie A, Coiffier G, et al. CD16- positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol. 2017 Jul 14;36(7):1649–54.spa
dc.relation.referencesYamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol. 2001 Oct;31(10):2936–41.spa
dc.relation.referencesChizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015 Sep 8;37(5):519–28.spa
dc.relation.referencesO’Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012 Sep 1;51(9):1540–9.spa
dc.relation.referencesBrown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019 Feb 18;195(3):310–21.spa
dc.relation.referencesKalogerou A. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis. 2005 Aug 1;64(8):1233–5.spa
dc.relation.referencesThoreau B, Chaigne B, Renaud A, Mouthon L. Pathophysiology of systemic sclerosis. Presse Med. 2021 Apr;50(1):104087.spa
dc.relation.referencesHua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Pathologie Biologie. 2015 Apr;63(2):61–8.spa
dc.relation.referencesAsano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020 Aug 19;9(9):2687.spa
dc.relation.referencesHASEGAWA M. B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis. J Dermatol. 2010 Jan 24;37(1):3–10.spa
dc.relation.referencesYoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76–82.spa
dc.relation.referencesRoberts AB, Sporn MB. Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β). Growth Factors. 1993 Jan 11;8(1):1–9.spa
dc.relation.referencesBoltjes A, van Wijk F. Human Dendritic Cell Functional Specialization in Steady- State and Inflammation. Front Immunol. 2014 Apr 1;5.spa
dc.relation.referencesAudiger C, Rahman MJ, Yun TJ, Tarbell K V., Lesage S. The Importance of Dendritic Cells in Maintaining Immune Tolerance. The Journal of Immunology. 2017 Mar 15;198(6):2223–31.spa
dc.relation.referencesGranot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al. Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life. Immunity. 2017 Mar;46(3):504–15.spa
dc.relation.referencesCarvalheiro T, Zimmermann M, Radstake TRDJ, Marut W. Novel insights into dendritic cells in the pathogenesis of systemic sclerosis. Clin Exp Immunol. 2020 Jun 11;201(1):25–33.spa
dc.relation.referencesShima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells. 2021 May 4;10(5):1104.spa
dc.relation.referencesKikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: Insensitivity to TGFβ1 stimulation. Biochem Biophys Res Commun. 1992 Aug;187(1):45–50.spa
dc.relation.referencesJuhl P, Bondesen S, Hawkins CL, Karsdal MA, Bay-Jensen AC, Davies MJ, et al. Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis. Sci Rep. 2020 Oct 14;10(1):17300.spa
dc.relation.referencesIgarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis. Journal of Investigative Dermatology. 1995 Aug;105(2):280–4.spa
dc.relation.referencesAspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.spa
dc.relation.referencesUmehara H, Kumagai S, Ishida H, Suginoshita T, Maeda M, Imura H. Enhanced production of interleukin‐2 in patients with progressive systemic sclerosis. hyperactivity of cd4‐positive t cells? Arthritis Rheum. 1988 Mar 29;31(3):401–7.spa
dc.relation.referencesMaria ATJ, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, et al. De la fibrogenèse à la fibrose : mécanismes physiopathologiques et présentations cliniques. Rev Med Interne. 2020 May;41(5):325–9.spa
dc.relation.referencesPannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol. 2004 Nov;16(6):739–45.spa
dc.relation.referencesAdriana Acosta Gómez. El fibroblasto: su origen, estructura, funciones y heterogeneidad. Universitas Odonto. 2006;25(57):26–33.spa
dc.relation.referencesOrnitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. WIREs Developmental Biology. 2015 May 13;4(3):215–66.spa
dc.relation.referencesDenton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006 Mar;2(3):134–44.spa
dc.relation.referencesDamoiseaux J, Potjewijd J, Smeets RL, Bonroy C. Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. J Transl Autoimmun. 2022;5:100141.spa
dc.relation.referencesChen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.spa
dc.relation.referencesvan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013 Nov;65(11):2737–47.spa
dc.relation.referencesAnna Bazsó, Emese Kiss. The Role of Biomarkers in the Pathogenesis, Clinical Manifestations, and Therapeutic Approach in Systemic Sclerosis. Preprints (Basel). 2023 Aug 8;spa
dc.relation.referencesDomsic RT, Medsger TA. Autoantibodies and Their Role in Scleroderma Clinical Care. Curr Treatm Opt Rheumatol. 2016 Sep 14;2(3):239–51.spa
dc.relation.referencesCavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2022 Jun 18;64(3):412–30.spa
dc.relation.referencesKowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–39.spa
dc.relation.referencesChen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.spa
dc.relation.referencesChen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.spa
dc.relation.referencesUtsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.spa
dc.relation.referencesUtsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.spa
dc.relation.referencesFarmaki E, Chatzistamou I, Kiaris H. Human MCP Chemokine Cluster. In: Encyclopedia of Signaling Molecules. Cham: Springer International Publishing; 2018. p. 2482–9.spa
dc.relation.referencesBarinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.spa
dc.relation.referencesMendez-Enriquez E, García-Zepeda EA. The multiple faces of CCL13 in immunity and inflammation. Inflammopharmacology. 2013 Dec 12;21(6):397–406.spa
dc.relation.referencesGarcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 1996 Dec 15;157(12):5613–26.spa
dc.relation.referencesLi L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.spa
dc.relation.referencesBarinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.spa
dc.relation.referencesHein H, Schlüter C, Kulke R, Christophers E, Schröder JM, Bartels J. Genomic Organization, Sequence Analysis and Transcriptional Regulation of the Human MCP-4 Chemokine Gene (SCYA13) in Dermal Fibroblasts: A Comparison to Other Eosinophilic β-Chemokines. Biochem Biophys Res Commun. 1999 Feb;255(2):470–6.spa
dc.relation.referencesGambichler T, Yilmaz E, Höxtermann S, Kolios A, Moritz R, Bechara FG, et al. Serum CCL13 levels in patients with systemic sclerosis and controls. British Journal of Dermatology. 2011 Jul;165(1):216–8.spa
dc.relation.referencesPetering H, Höchstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol. 1998 Jan 15;160(2):555–8.spa
dc.relation.referencesLi L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.spa
dc.relation.referencesYanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).spa
dc.relation.referencesPolania Maria Daniela, Higuera Maria. FRECUENCIA DE POLIAUTOINMUNIDAD EN ESCLEROSIS SISTÉMICA. Universidad del Rosario . 2020 Jun;spa
dc.relation.referencesPrince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers. 2005 Jan 20;10(sup1):44–9.spa
dc.relation.referencesVona R, Giovannetti A, Gambardella L, Malorni W, Pietraforte D, Straface E. Oxidative stress in the pathogenesis of systemic scleroderma: An overview. J Cell Mol Med. 2018 Jul 17;22(7):3308–14.spa
dc.relation.referencesMinier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087-93spa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.subject.proposalAutoinmunidadspa
dc.subject.proposalEsclerosis Sistémicaspa
dc.subject.proposalRespuesta inmunespa
dc.subject.proposalProteínaspa
dc.subject.proposalBiomarcadorspa
dc.subject.proposalConcentraciónspa
dc.subject.proposalFisiopatologíaspa
dc.subject.proposalDiagnosticospa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_14cbspa


Ficheros en el ítem

Thumbnail
Nombre:
MCP4 COMO BIOMARCADOR DE DIAGN ...
Tamaño:
1.594Mb
Formato:
PDF
Ver/
Thumbnail
Nombre:
MCP4 COMO BIOMARCADOR DE DIAGN ...
Tamaño:
2.976Mb
Formato:
Microsoft Word 2007
Ver/
Thumbnail
Nombre:
CARTA DERECHOS DE AUTOR IP ...
Tamaño:
98.58Kb
Formato:
PDF
Ver/
Thumbnail
Nombre:
FORMATO IDENTIFICACIÓN TRABAJO ...
Tamaño:
265.0Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
Excepto si se señala otra cosa, la licencia del ítem se describe como Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024